Drug Profile
Research programme: anti-c-MET monoclonal antibodies - A-CUBE/Wakunaga Pharmaceutical Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator A-CUBE
- Developer A-CUBE; Wakunaga Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA